Comprehensive Assessment of Acute Isolated or Prominent Dysarthria in the Emergency Department: A Neuro-Emergency Expert's Experience beyond Stroke.
Soon-Ho LeeSang Ook HaJin-Hyouk KimWon-Seok YangYoung-Sun ParkTae-Jin ParkPublished in: Brain sciences (2022)
We investigated the clinical characteristics, neuroimaging findings, and final diagnosis of patients with acute isolated or prominent dysarthria who visited the emergency department (ED) between 1 January 2020 and 31 December 2021. Of 2028 patients aged ≥ 18 years with neurologic symptoms treated by a neuro-emergency expert, 75 with acute isolated or predominant dysarthria within 1 week were enrolled. Patients were categorized as having isolated dysarthria ( n = 28, 37.3%) and prominent dysarthria ( n = 47, 62.7%). The causes of stroke were acute ischemic stroke (AIS) ( n = 37, 49.3%), transient ischemic attack (TIA) ( n = 14, 18.7%), intracerebral hemorrhage ( n = 1, 1.3%), and non-stroke causes ( n = 23, 30.7%). The most common additional symptoms were gait disturbance or imbalance ( n = 8, 15.4%) and dizziness ( n = 3, 13.0%) in the stroke and non-stroke groups, respectively. The isolated dysarthria group had a higher rate of TIA ( n = 7, 38.9%), single and small lesions ( n = 10, 83.3%), and small-vessel occlusion in Trial of Org 101072 in acute stroke treatment ( n = 8, 66.7%). Acute isolated or prominent dysarthria in the ED mostly presented as clinical symptoms of AIS, but other non-stroke and medical causes were not uncommon. In acute dysarthria with ischemic stroke, multiple territorial and small and single lesions are considered a cause.
Keyphrases
- emergency department
- atrial fibrillation
- liver failure
- end stage renal disease
- respiratory failure
- acute ischemic stroke
- newly diagnosed
- cerebral ischemia
- healthcare
- ejection fraction
- chronic kidney disease
- drug induced
- public health
- aortic dissection
- peritoneal dialysis
- clinical trial
- prognostic factors
- hepatitis b virus
- mass spectrometry
- brain injury
- clinical practice
- combination therapy
- subarachnoid hemorrhage
- adverse drug
- electronic health record
- phase iii
- smoking cessation
- phase ii
- clinical evaluation